Glassclear and highly resistant


With the takeover of the Chemicals division of Dynamit Nobel AG in 1988, Evonik acquired the transparent, amorphous polyamide TROGAMID® T. Dynamit Nobel launched this first polymer of dimethyl terephthalate and trimethylhexamethylene diamine on the market as early as 1968. Substitution of the aromatic components by aliphatic monomers led in 1991 to transparent polyamides with inherently better UV resistance. Systematic selection of the cycloaliphatic diamine and 1,12-dodecanedioic acid monomers resulted in a crystallizable, permanently transparent polyamide, distinguished as crystalline by the name TROGAMID® CX, in 1995.

Nomenclature of semi-aromatic aliphatic polyamides

Nomenclature ISO 1043
Nomenclature ISO 1874
CX grades
not applicable
cycloaliphatic diamine dodecanedioic acid

Common transparent polyamides consist in partially aromatic units that impart rigidity and high heat resistance.

Replacing aromatic constituents with aliphatic monomers improves the UV stability of transparent polyamides. TROGAMID® CX7323 is an example of this type of polyamides. By selecting specific monomers the crystallites are so small that they do not scatter visible light, and the material appears transparent to the human eye—a property known as microcrystallinity.

In 2020, Evonik stopped production of the amorphous polyamide TROGAMID® T originally acquired from Dynamit Nobel AG.

TROGAMID® Care compounds were subject to specific evaluation. They are based on the semi-crystalline compounds. For more information, please visit the page about our high-performance plastics in medical applications.